Workflow
Apitox
icon
Search documents
Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program
Businesswire· 2025-09-12 01:54
Core Insights - The FDA has released draft guidance on the development of non-opioid pain therapies, which is expected to benefit Apimeds Pharmaceuticals' lead program, Apitox, aimed at treating chronic osteoarthritis pain [1]. Company Summary - Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) is positioned to accelerate its lead program, Apitox, in response to the FDA's new draft guidance [1]. Industry Summary - The draft guidance titled "Development of Non-Opioid Analgesics for Chronic Pain" is a significant regulatory development that may influence the landscape for non-opioid pain management therapies [1].
Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering
Globenewswire· 2025-05-12 21:14
Core Viewpoint - Apimeds Pharmaceuticals US, Inc. has successfully completed its initial public offering, raising $13.5 million to fund clinical trials and other operational needs [1][3]. Group 1: Initial Public Offering Details - The company closed its initial public offering of 3,375,000 shares at a price of $4.00 per share, with trading commencing on May 9, 2025 [1]. - Gross proceeds from the offering amounted to $13.5 million before expenses [1]. - Underwriters were granted a 45-day option to purchase an additional 506,250 shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to fund a Phase III clinical trial for knee osteoarthritis [3]. - The company plans to initiate at least one non-registered corporate sponsorship study in multiple sclerosis [3]. - Proceeds will also be allocated for manufacturing its product candidate and general working capital needs [3]. Group 3: Company Overview - Apimeds is a clinical stage biopharmaceutical company developing Apitox, a bee venom-based toxin with potential therapeutic effects [6]. - The product is being developed as a treatment for knee pain in osteoarthritis patients who do not respond adequately to conventional therapies [6].
美国IPO一周回顾及前瞻:上周有5家企业IPO(含SPAC),9家递交申请(含SPAC)
Sou Hu Cai Jing· 2025-05-12 11:12
Group 1: Recent IPOs - Five new companies went public last week, including two SPACs [1] - Aspen Insurance (AHL) raised $398 million at a market cap of $2.78 billion, closing up 15% [2][1] - American Integrity (AII) raised $110 million at a market cap of $313 million, closing up 8% [2][1] - Apimeds Pharmaceuticals US (APUS) raised $14 million with a market cap of $47 million, closing down 45% [1] Group 2: Upcoming IPOs - eToro Group (ETOR) plans to raise $480 million with a market cap of $4.5 billion, focusing on combining social networking with trading [5][6] - OMS Energy Technologies (OMSE) plans to raise $50 million with a market cap of $399 million, primarily serving the oil and gas sector [5][6] - Antalpha Platform Holding (ANTA) plans to raise $46 million with a market cap of $309 million, providing financing solutions for the digital asset industry [6][7] Group 3: Filings and Market Activity - Omada Health (OMDA) filed for $100 million to provide digital health tools for chronic conditions [3] - Several SPACs are targeting various sectors, including energy storage and technology [3]
Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering
Globenewswire· 2025-05-08 21:00
Core Viewpoint - Apimeds Pharmaceuticals US, Inc. has announced the pricing of its initial public offering (IPO) of 3,375,000 shares at $4.00 per share, aiming to raise approximately $13.5 million in gross proceeds [1][2]. Group 1: IPO Details - The IPO is expected to close on May 12, 2025, and shares will begin trading on the NYSE American under the symbol "APUS" on May 9, 2025 [2]. - The underwriters have a 45-day option to purchase an additional 506,250 shares at the public offering price, and they have been issued warrants for up to 168,750 shares [2]. Group 2: Use of Proceeds - The net proceeds from the IPO will be utilized to fund a Phase III clinical trial for knee osteoarthritis, initiate a corporate sponsorship study in multiple sclerosis, manufacture the product candidate, and cover general working capital needs [3]. Group 3: Company Overview - Apimeds is a clinical stage biopharmaceutical company developing Apitox, a bee venom-based toxin administered intradermally, which is being targeted as a treatment for osteoarthritis in patients who do not respond to conventional therapies [6].